Navigating Early Scientific Advice for Pricing and Market Access Success

Event Host

Event Description

As the regulatory and market access landscape evolves across Europe, understanding how and when to engage with HTAs is critical — especially ahead of pivotal Phase III trials. This webinar will introduce Remap’s proven BRAVE framework, equipping you with the tools to:

• Ask the right questions and gain tailored non-binding payer feedback
• Identify and address evidence gaps early
• Align cross-functional teams around market access strategy
• Navigate formal and informal advice routes (NICE, G-BA, EU JSC)
• Strengthen pricing and reimbursement outcomes

Join Graham Foxon and Charlie Hewitt for an actionable and insightful session designed to help pharma and biotech teams make the most of early scientific advice for health technology assessment (HTA) bodies.

Whether you’re in market access, R&D, medical, or commercial roles, this session will help you position your assets for long-term success.

Speakers:

• Graham Foxon – Managing Director
• Charlie Hewitt – Senior Director – Consulting team